BeyondAirInc . (NASDAQ:XAIR) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Valuation & Earnings
This table compares BeyondAirInc . and Cerus’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BeyondAirInc .||$7.72 million||5.80||-$6.56 million||($0.84)||-4.96|
|Cerus||$60.91 million||10.16||-$57.56 million||($0.44)||-10.02|
Institutional & Insider Ownership
5.4% of BeyondAirInc . shares are owned by institutional investors. Comparatively, 72.9% of Cerus shares are owned by institutional investors. 7.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
BeyondAirInc . has a beta of -0.27, suggesting that its stock price is 127% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500.
This table compares BeyondAirInc . and Cerus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings for BeyondAirInc . and Cerus, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cerus has a consensus target price of $8.00, suggesting a potential upside of 81.41%. Given BeyondAirInc .’s higher probable upside, research analysts clearly believe BeyondAirInc . is more favorable than Cerus.
Cerus beats BeyondAirInc . on 9 of the 13 factors compared between the two stocks.
BeyondAirInc . Company Profile
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Cerus Company Profile
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.